Medicine & pharmacy

TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe

Partnership streamlines ordering process & reduces lead times to support TriLink’s European customer projects from start to finish SAN DIEGO–(BUSINESS WIRE)– TriLink BioTechnologies (TriLink®), a...

Avanzanite Bioscience Benoemt Chief Financial Officer

Abdel Omari’s benoeming tot Chief Financial Officer versterkt Avanzanite’s financieel leiderschap, bevordert de uitbreiding naar 26 Europese landen en stimuleert nieuwe partnerschappen Meneer Omari’s uitzonderlijk...

Avanzanite Bioscience Appoints Chief Financial Officer

Abdel Omari’s appointment as Chief Financial Officer strengthens Avanzanite’s financial leadership, driving expansion into 26 European countries and fostering new partnerships Mr. Omari’s exceptional financial...

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease progression or death by 37% versus chemotherapy Datopotamab deruxtecan...

GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand

New $138 million facility at GE HealthCare’s Cork manufacturing site will enable 25 million more patient doses of contrast media per year by the end...

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

– Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY – – Agreement for CASGEVY in transfusion-dependent beta thalassemia...

IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)

First results from the phase IIIb RELAX clinical trial reinforce the high and sustained efficacy of single treatment of RelabotulinumtoxinA (RelfydessTM) for moderate to severe...

Wereldberoemde atleet Charles Leclerc werkt samen met Eight Sleep om herstel opnieuw te definiëren

Leclerc sluit zich aan bij ‘s werelds toonaangevende Sleep Fitness Company als ambassadeur en investeerder om te bewijzen dat topprestaties beginnen met een optimale slaap...

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

— JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than...

Ferrer wordt erkend voor zijn beste ethiek- en nalevingsprogramma

Ferrer behaalt Compliance Leader Verification™, de prestigieuze erkenning die verleend wordt door Ethisphere Na een grondige beoordeling van zijn ethiek- en nalevingsprogramma bevestigt het bedrijf...

Owkin maakt bekend dat de eerste patiënt zijn dosis werd toegediend in het via AI geoptimaliseerde klinische onderzoek Fase I van OKN4395, een unieke drievoudige inhibitor van EP2/EP4/DP1 voor patiënten met een vaste tumor

OKN4395 is het eerste ontwikkelingsprogramma van Owkin dat gebruik maakt van K1.0, het door AI aangestuurde besturingssysteem van Owkin, van asset-selectie tot optimalisatie van de...

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

Second- and third-line treatment for adults with mycosis fungoides or Sézary syndrome reimbursed by Croatia’s National Health Insurance Fund (NHIF), effective as of 15th November...

Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a...

Ferrer is Recognized for Its Best-in-class Ethics and Compliance Program

Ferrer achieves Compliance Leader Verification™, the prestigious recognition granted by Ethisphere Following an exhaustive review of its ethics and compliance program, the company reaffirms its...

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber...